Integrin interaction inhibitors for the treatment of cancer
US8853149B2 · kind B2 · utility
6Cited by
13References
102Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 21, 2011 |
| Grant date | Oct 7, 2014 |
| Priority date | — |
| Expiry date | Mar 21, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.